GIST Awareness Day – Kenya
GIST Awareness Day in Kenya, 2019. GAD began in 2014 by The Life Raft Group, to raise awareness on GIST worldwide.
GIST Awareness Day – Chile
GIST Awareness Day in Chile, 2019. GAD began in 2014 by The Life Raft Group, to raise awareness on GIST worldwide.
GIST Do It: All Year Long
GIST DO IT is an amazing way to educate the medical community and the general public about GIST. We would like to take it to the next level and encourage everyone to “GIST DO IT All Year Long.”
LRG Assisted in CAP Guidelines Modifications with a Diagnostic Algorithm
The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.
Patient of the Month for August: Guy Jones
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Guy Jones shares his story.
Rozlytrek™ (entrectinib) by Approved by FDA
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), The FDA has also granted accelerated approval to Rozlytrek for the treatment of [...]
Deciphera Releases Positive Trial Results for Ripretinib
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]
Treatment Responses in SDH-deficient GIST – LRG Science
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
LRG Releases Annual Report for 2018
In 2018, The Life Raft Group continued its dedication to patients with GIST, working diligently to enhance survival and quality of life through research, information, education, advocacy, and outreach & engagement. These efforts would [...]
Blueprint Medicines Announces Next Step for Avaprinitib
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]